<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03728842</url>
  </required_header>
  <id_info>
    <org_study_id>IUCRO-0042</org_study_id>
    <secondary_id>1011003667</secondary_id>
    <nct_id>NCT03728842</nct_id>
  </id_info>
  <brief_title>Spontaneous Regression in Metastatic Melanoma and Renal Cell Carcinoma</brief_title>
  <official_title>Blood Drawing for Study of Peripheral Blood T-lymphocytes and Other Parameters in Patients With Metastatic Melanoma and Renal Cell Cancer With Spontaneous Regression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to collect blood and clinical data from patients with metastatic
      melanoma and renal cell cancer who have experienced spontaneous regression for studies of
      immune response and other factors that may influence these occurrences.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Spontaneous regression in patients with metastatic cancer is an incredibly rare event. It has
      been described after infection in cancer patients and also rarely in patients with renal cell
      cancer (usually after resection of the renal primary) and, less commonly, in patients with
      metastatic melanoma.

      Primary Objective To collect peripheral blood from patients with metastatic melanoma and
      renal cell cancer and spontaneous regression for studies of immune response and other
      studies.

      Secondary Objective To collect clinical data from subjects registered to this study. Clinical
      data collection will include demographics and cancer characteristics, history and treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 24, 2003</start_date>
  <completion_date type="Anticipated">March 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of blood samples collected</measure>
    <time_frame>1 year</time_frame>
    <description>samples collected from metastatic melanoma and renal cell cancer patients</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Melanoma; Renal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Spontaneous regression</arm_group_label>
    <description>Patients must have metastatic melanoma or renal cell cancer with spontaneous regression.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood collection for laboratory studies</intervention_name>
    <description>Peripheral whole blood will be collected</description>
    <arm_group_label>Spontaneous regression</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Data collection from medical record</intervention_name>
    <description>Clinical data such as demographics and cancer characteristics, history and treatment will be collected</description>
    <arm_group_label>Spontaneous regression</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with metastatic melanoma and renal cell cancer and spontaneous regression.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. â‰¥ 18 years old at the time of informed consent

          2. Ability to provide written informed consent and HIPAA authorization

          3. Patients must have metastatic melanoma or renal cell cancer with spontaneous
             regression.

          4. Willingness to undergo phlebotomy for research blood samples

        Exclusion Criteria

          1. Concurrent disease or condition that would make the patient inappropriate for study
             participation or any serious medical or psychiatric disorder that would interfere with
             the subject's safety

          2. Dementia, altered mental status, or any psychiatric condition that would prohibit the
             understanding or rendering of informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Theodore Logan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Theodore Logan, MD</last_name>
    <phone>317-948-7576</phone>
    <email>tlogan@iu.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Indiana University Simon Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sheila Dropcho, RN</last_name>
      <phone>317-278-4191</phone>
      <email>sdropcho@iupui.edu</email>
    </contact>
    <investigator>
      <last_name>Theodore Logan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>October 5, 2018</study_first_submitted>
  <study_first_submitted_qc>October 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 2, 2018</study_first_posted>
  <last_update_submitted>October 31, 2018</last_update_submitted>
  <last_update_submitted_qc>October 31, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indiana University School of Medicine</investigator_affiliation>
    <investigator_full_name>Theodore Logan</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>metastatic disease</keyword>
  <keyword>spontaneous regression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

